BACKGROUND: Deep brain stimulation of the subthalamic nucleus (STN-DBS) is an established treatment for patients with Parkinson's disease (PD). Speech impairment is a frequent side effect of the surgery. This study examined the efficacy of an intensive speech treatment, the Lee Silverman Voice Treatment (LSVT) on dysarthria after STN-DBS. METHODS: The LSVT was administered to 10 patients with STN-DBS (surgical group) and 10 patients without (medical group). Patients were assessed before, immediately after, and 6 months following the speech treatment using sustained phonation, a speech intelligibility scale, and monologue. Vocal loudness, speech intelligibility, and perceptual ratings were the primary outcome measures. RESULTS: Vocal loudness and perceptual scores improved significantly across tasks for the medical group only. Speech intelligibility did not significantly change for either group. Results in the surgical group were variable, with some patients deteriorating. CONCLUSIONS: Treatment of dysarthria following STN-DBS needs further investigation because of the variable response to LSVT.
BACKGROUND: Deep brain stimulation of the subthalamic nucleus (STN-DBS) is an established treatment for patients with Parkinson's disease (PD). Speech impairment is a frequent side effect of the surgery. This study examined the efficacy of an intensive speech treatment, the Lee Silverman Voice Treatment (LSVT) on dysarthria after STN-DBS. METHODS: The LSVT was administered to 10 patients with STN-DBS (surgical group) and 10 patients without (medical group). Patients were assessed before, immediately after, and 6 months following the speech treatment using sustained phonation, a speech intelligibility scale, and monologue. Vocal loudness, speech intelligibility, and perceptual ratings were the primary outcome measures. RESULTS: Vocal loudness and perceptual scores improved significantly across tasks for the medical group only. Speech intelligibility did not significantly change for either group. Results in the surgical group were variable, with some patients deteriorating. CONCLUSIONS: Treatment of dysarthria following STN-DBS needs further investigation because of the variable response to LSVT.
Authors: Shimon Sapir; Jennifer L Spielman; Lorraine O Ramig; Brad H Story; Cynthia Fox Journal: J Speech Lang Hear Res Date: 2007-08 Impact factor: 2.297
Authors: L O Ramig; S Sapir; S Countryman; A A Pawlas; C O'Brien; M Hoehn; L L Thompson Journal: J Neurol Neurosurg Psychiatry Date: 2001-10 Impact factor: 10.154
Authors: F Klostermann; F Ehlen; J Vesper; K Nubel; M Gross; F Marzinzik; G Curio; T Sappok Journal: J Neurol Neurosurg Psychiatry Date: 2007-08-31 Impact factor: 10.154
Authors: Jennifer Spielman; Lorraine O Ramig; Leslie Mahler; Angela Halpern; William J Gavin Journal: Am J Speech Lang Pathol Date: 2007-05 Impact factor: 2.408
Authors: András Jakab; Beat Werner; Marco Piccirelli; Kázmér Kovács; Ernst Martin; John S Thornton; Tarek Yousry; Gabor Szekely; Ruth O'Gorman Tuura Journal: Front Neuroanat Date: 2016-07-12 Impact factor: 3.856